Enzo Life Sciences Intelligence Profile

enzolifesciences.comLast reviewed: October 20, 2026Research coverage: 77%

Overall data confidence:Unknown

Identity confidence

Moderate

7 of 10 identity fields independently documented

Corporate continuity

Continuous operation at enzolifesciences.com since its 2002 registration; storefront live with current products as of 2026-10-20.

Based on domain history and corporate record fields

Regulatory exposure

None identified

Derived from published risk flags

Evidence integrity

High

6 of 7 testing fields documented

Transaction transparency

Low

1 of 5 commercial fields documented

Change activity

None tracked

0 change events tracked

Research Incomplete

Research coverage for this vendor is 77%. Our research on Enzo Life Sciences remains incomplete — what we have verified so far is published below, and research is continuing.

Still to research:

Research coverage ≥ 80%
Registration jurisdiction researched (state_of_registration)
Refund policy reviewed (refund_return_policy)
Shipping policy reviewed (shipping_fulfillment_representations)
Payment methods reviewed (accepted_payment_methods)
Public summary reviewed

Overview#

Established research-products business (Enzo Life Sciences, Inc., Farmingdale, NY) at enzolifesciences.com (registered 2002-07-17), wholly owned by Enzo Biochem, Inc. FIT: passes the peptide gate with honest scoping — peptides are a minority line within a broad reagent catalog (portfolio expressly includes 'antibodies, proteins, peptides and other related compounds'; peptide-based products and peptide-substrate kits are sold, e.g., Nupherin peptide-based transfection reagent; FLUOR DE LYS peptide-substrate assay kits), and product pages offer lot-number CoA lookup. HIGH items are PARENT-level and clinical-labs-attributed, not Life Sciences product findings: the April 2023 ransomware attack led to a $4.5M NY/NJ/CT AG settlement (Aug 2024, settled) and a $7.5M class-action settlement (2025, settled, no admission). FDA/FTC searches for the vendor: No Record Found in the defined searches. Material corporate change: parent taken private by Battery Ventures (merger closed Aug 20, 2025) after the 2023 Labcorp divestiture. Gaps: subsidiary's own state of registration, formation date, registered agent, CoA test recency, and payment/refund/shipping/terms documents were not retrieved in this pass (8 fields Unknown).

Company Identity#

Vendor Brand NameEnzo Life Sciences

HighSource: Enzo Life Sciences product pages (enzolifesciences.com)

Primary Website Domainenzolifesciences.com

ModerateSource: Enzo Life Sciences — official website (intake domain confirmation)

Legal Entity NameEnzo Life Sciences, Inc. (wholly owned subsidiary of Enzo Biochem, Inc.)

HighSource: Nasdaq — Enzo Biochem press release (Enzo Life Sciences as remaining operating segment/subsidiary)

State of RegistrationNot independently verified

UnknownSource: Enzo Biochem corporate history sources (parent incorporated 1976, New York) reviewed; subsidiary registry record not retrieved

Entity StatusOperating — enzolifesciences.com is live with a current catalog (2026). Parent Enzo Biochem, Inc. became a privately held subsidiary of Bethpage Parent, Inc. (Battery Ventures) on August 20, 2025 and ceased public trading.

ModerateSource: Panabee — 'Enzo Biochem Finalizes Merger at $0.70 Per Share, Transitions to Private Ownership' (merger effective Aug 20, 2025)

Incorporation / Formation DateNot independently verified

UnknownSource: Enzo Biochem corporate profiles (parent incorporated 1976, New York) reviewed; subsidiary formation record not retrieved

Named Principals / ManagersParent-level: Elazar Rabbani, PhD — founder of Enzo Biochem (Chairman & CEO historically); Kara Cannon — Interim CEO from September 2023 (director until the August 2025 merger); Patricia Eckert — Chief Financial Officer (per April 2025 company release); Steven J. Pully — Board Chairman from October 2023 until the August 2025 merger. Post-merger private-company management not publicly verified.

ModerateSource: Stockwatch — Enzo Biochem release (Apr 22, 2025): Patricia Eckert, CFO; OTCQX transfer

Registered AgentNot independently verified

UnknownSource: Enzo Life Sciences website reviewed (no registered agent disclosed)

Operating Address10 Executive Blvd., Farmingdale, NY 11735, USA

ModerateSource: Enzo Safety Data Sheet (Jan 2025) — supplier address 10 Executive Blvd., Farmingdale, NY 11735

Address ConsistencyMostly consistent — 10 Executive Blvd., Farmingdale, NY 11735 appears in Enzo's own SDS documents and parent annual reports for the Life Sciences operation. One third-party directory (GlobalData) lists the parent HQ as 21 Executive Blvd., Farmingdale, NY 11735; that 10-vs-21 discrepancy in third-party data was not resolved in this pass. The parent's historical executive office was 527 Madison Ave., New York, NY 10022.

ModerateSource: Enzo SDS / annual-report sources (10 Executive Blvd.) vs GlobalData profile (21 Executive Blvd.)

Domain and Digital Identity#

Domain Registration Date2002-07-17

HighSource: Verisign RDAP record for enzolifesciences.com

Domain Ownership / Registrar Change HistoryRegistrar: Network Solutions, LLC; registrant identity redacted in RDAP; last changed 2025-05-18; expires 2028-07-17. No evidence of an ownership transfer.

ModerateSource: Verisign RDAP record for enzolifesciences.com

Website ContinuityContinuous operation at enzolifesciences.com since its 2002 registration; storefront live with current products as of 2026-10-20.

ModerateSource: Enzo Life Sciences product pages (live, current)

Contact Channel IntegrityFarmingdale telephone (631) 694-7070 published in parent annual reports/SDS documents; parent investor contact (Patricia Eckert, CFO, 631-755-5500, peckert@enzo.com) published in 2025 company releases; ordering/support channels on enzolifesciences.com.

ModerateSource: Stockwatch — Enzo Biochem release (Apr 22, 2025): Patricia Eckert, CFO, 631-755-5500, peckert@enzo.com

Regulatory and Legal History#

FDA Warning Letter HistoryNo Record Found in the defined search

HighSource: Defined web search of FDA warning letters — no letter naming Enzo entities

FDA Recall / Safety Action HistoryNo Record Found in the defined search

HighSource: Defined web search of FDA recalls — no action naming Enzo entities

FDA Import Alert / Detention ExposureNo Record Found in the defined search

HighSource: Defined web search of FDA import alerts — no alert naming Enzo entities

FTC Enforcement HistoryNo Record Found in the defined search

HighSource: Defined web search of FTC enforcement — no action naming Enzo entities

State Regulatory / Attorney General ActionsHIGH (parent-level) — August 13, 2024: Enzo Biochem, Inc. agreed to a $4.5 million settlement with the Attorneys General of New York, New Jersey and Connecticut (NY $2.8M; NJ ~$930K; CT ~$743,110) over deficient data-security safeguards exposed by the April 2023 ransomware attack on its clinical-laboratory business, plus mandated security improvements. Status: settled. Attribution: the action was against the parent company over its (now-divested) clinical labs' patient data — NOT over Enzo Life Sciences reagent products.

HighSource: New York Attorney General — Enzo Biochem $4.5M multistate data-security settlement (Aug 13, 2024)

Relevant Civil LitigationParent-level: consumer class-action litigation over the April 2023 ransomware attack — in which attackers accessed/exfiltrated clinical test information of approximately 2.47 million individuals (including more than 600,000 Social Security numbers; ~1.46M New Yorkers) — was settled for $7.5 million (disclosed in an SEC filing; reported January 2025), with no admission of wrongdoing; class members could claim up to $10,000 in documented losses plus two years of credit monitoring. Attribution: Enzo Biochem, Inc. / former Enzo Clinical Labs operations, not Enzo Life Sciences products. Status: settled.

ModerateSource: SEC filing disclosure reported Jan 2025 — $7.5M Enzo ransomware class-action settlement

Criminal / Injunctive ProceedingsNo Record Found in the defined search — no criminal proceeding or injunction against Enzo Life Sciences or Enzo Biochem was identified; the 2023 ransomware incident produced the AG settlement and civil class action recorded in their own fields (the company was the attack victim in those matters).

ModerateSource: Defined web search of DOJ/court actions — none naming Enzo entities as defendant

Testing and COA Evidence#

Public COA AvailabilityProduct pages on enzolifesciences.com provide a 'CofA' document link alongside Datasheet/Manual/SDS, and a lot-number Certificate of Analysis lookup ('Certificate of Analysis — Please enter the lot number').

HighSource: Enzo Life Sciences product page — CofA document link (ADI-901-017A)

Batch / Lot SpecificityLot-specific — Certificates of Analysis are retrieved by entering the product lot number on the vendor's site.

HighSource: Enzo Life Sciences product page — 'Certificate of Analysis: Please enter the lot number'

Independent Laboratory IdentityNo independent third-party testing laboratory identified — Certificates of Analysis are issued by Enzo Life Sciences itself. The company states ISO & GMP certifications for its operations (company claim).

ModerateSource: Enzo Life Sciences product pages (vendor-issued CofAs)

COA Verification StatusLot-number CoA lookup is provided on the vendor's own site; verification is vendor-hosted, with no independent verification service identified.

ModerateSource: Enzo Life Sciences — lot-number CoA lookup

Test RecencyNot independently verified

UnknownSource: Enzo Life Sciences product pages reviewed (CoA test dates not verified)

Testing CoverageProduct pages publish specifications including purity (e.g., ≥90% or ≥95% by SDS-PAGE for protein products), formulation, and application data, with Datasheet/Manual/SDS/CofA documents per product.

ModerateSource: Enzo Life Sciences product page — specifications (Adiponectin (mouse), recombinant: Purity ≥90% SDS-PAGE)

Evidence ConsistencyNo evidence-integrity findings identified in the defined searches. Enzo was not among the 15 companies named in the August 2026 Richardson & David vendor antibody-image dataset (per C&EN's published list).

ModerateSource: C&EN — report on the Richardson & David dataset listing the 15 companies (Enzo not listed)

Payment, Refund and Shipping#

Accepted Payment MethodsNot independently verified

UnknownSource: Enzo Life Sciences product page (account pricing; payment methods not stated)

Refund / Return PolicyNot independently verified

UnknownSource: Enzo Life Sciences product page (Worry-Free Guarantee referenced; terms not retrieved)

Shipping & Fulfillment RepresentationsNot independently verified

UnknownSource: Enzo Life Sciences website (shipping terms not retrieved)

Terms / Policy StabilityNot independently verified

UnknownSource: Enzo Life Sciences website (terms of sale not retrieved)

Customer Complaint PatternNo Record Found in the defined search for the Life Sciences products business. Consumer complaints identified in searches relate to the former Enzo Clinical Labs patient-testing business (parent company), a different operation that was sold in 2023.

ModerateSource: Defined web complaint search — no pattern naming Enzo Life Sciences products

Material Changes#

No material changes recorded.

Sources#

Enzo Life Sciences — official website (intake domain confirmation)Tier 2 · Official/CommercialVendor Website

Retrieved: October 20, 2026